title: Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.
abstract: OBJECTIVE
  Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain.
  
  
  METHODS
  1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF(10) broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1).
  
  
  RESULTS
  Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV 16, 18, 33, 31, 45, 35, 52 and 56, accounting for more than 90% of cases. HPV 16 and 18 contributed to 72.4% of all HPV positive ICC cases. In cervical adenocarcinomas, this contribution increased up to 94%. HPV 16 and 18 relative contributions showed a stable pattern over the 60 year study period. HPV 45, 18 and 16-positive ICC cases presented at younger ages than cases with other HPV types (adjusted mean age: 43.8, 45.2, 52.6 and 57.7 years, respectively).
  
  
  CONCLUSIONS
  HPV 16 and 18 accounted together for a 72.4% of positive cases, with no statistically significant changes in their relative contributions over the last decades. In 94% of cervical adenocarcinomas we identified at least one of the two HPV types included in the current vaccines (HPV 16/18). Results suggest a major impact of HPV vaccines on reduction of ICC burden in Spain in the HPV vaccinated cohorts.
authors: IDIBELL, Institut Català d'Oncologia - Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain. lalemany@iconcologia.net
authors: Laia
authors: L
authors: Alemany
authors: Cristina
authors: C
authors: Pérez
authors: Sara
authors: S
authors: Tous
authors: Antonio
authors: A
authors: Llombart-Bosch
authors: Belen
authors: B
authors: Lloveras
authors: Enrique
authors: E
authors: Lerma
authors: Rosa
authors: R
authors: Guarch
authors: Miguel
authors: M
authors: Andújar
authors: Adela
authors: A
authors: Pelayo
authors: Maria
authors: M
authors: Alejo
authors: Jaume
authors: J
authors: Ordi
authors: Joellen
authors: J
authors: Klaustermeier
authors: Julio
authors: J
authors: Velasco
authors: Nuria
authors: N
authors: Guimerà
authors: Omar
authors: O
authors: Clavero
authors: Xavier
authors: X
authors: Castellsagué
authors: Wim
authors: W
authors: Quint
authors: Nubia
authors: N
authors: Muñoz
authors: F Xavier
authors: FX
authors: Bosch
authors: Silvia
authors: S
authors: de Sanjosé
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000821:virology; D000328:Adult; D000368:Aged; D052685:Alphapapillomavirus / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification; D005260:Female; D005838:Genotype; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D052161:Human papillomavirus 18 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000235:genetics / Q000276:immunology; D013030:Spain / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000821:virology*
chemical_list: D053918:Papillomavirus Vaccines